Comparison of double dose plateletpheresis on the Fenwal Amicus, Fresenius COM.TEC and Trima Accel cell separators

Keklik, Muzaffer; Eser, Bülent; Kaynar, Leylagül; Öztürk, Ahmet; Yay, Mehmet; Birekul, A.; Öztekin, Mehmet Fevzi; Şıvgın, Serdar; Çetın, Mustafa; Ünal, Ali

doi:10.1016/j.transci.2014.08.022

Cited by 13 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study by Fontana et al [25] the PLT yield in DDP by Amicus was 6.06 9 10 11 . Similar were the findings by Keklik et al [26] as well (6.1 ± 0.9 9 10 11 ). The yield was 7.24 ± 0.53 9 10 11 in study by Jaipian et al [24] on DDP.…”

Section: Discussionsupporting

confidence: 92%

Double Dose Plateletpheresis: A Savior to Shrinking Donor Pool and Platelet Inventory Management

Makroo

Fadadu

Agrawal

et al. 2018

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

The double dose plateletpheresis (DDP) is considered to be a cost effective way of preparing platelets, owing to the low incidence of infectious complications and by also minimizing allogeneic donor exposure to the patients. We aimed at collecting DDP at our center and study its effect on donor hematological parameters, evaluate the product quality and the adverse donor reactions thereafter. Double Dose Platelet was collected from 160 eligible apheresis donors on Amicus cell separator (Fenwal, Inc. Three Corporate Drive Lake Zurich, IL, USA). The donor hematological parameters, product yield, adverse effects on the donors, collection efficiency (CE) and collection rate of the machine were noted. A total of 160 DDPs were collected. The total blood volume processed to achieve the yield of 6.0 9 1011 was 3673.5 ± 276.56 mL. The average yield achieved was 6.14 ± 0.26 9 1011. The average run time was 68.05 ± 6.25 min. Total ACD used was 408.33 ± 33.81 mL. We observed significant relation of pre-donation donor platelet count and platelet yield (p \ 0.001). The CE was 78.09 ± 5.15%. There was a significant drop in the post DDP platelet count (p \ 0.01) causing no adverse effect. Fourteen donors (8.75%) experienced mild citrate related adverse events. DDP does not lead to major adverse effects and post DDP hematological parameters are also within the acceptable range. It also helps to maintain apheresis platelet inventory, reduce donor exposure, reduce donor requirement and reduce the cost of the product.

show abstract

Section: Discussionsupporting

confidence: 92%

Double Dose Plateletpheresis: A Savior to Shrinking Donor Pool and Platelet Inventory Management

Makroo

Fadadu

Agrawal

et al. 2018

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

show abstract

“…[ 19 ] Efficient plateletpheresis is defined not only by platelet yield but also by blood volume processed, separation time, and the use of ACD. [ 22 ] Based on our findings, there is significant difference between Trima Accel ® and Haemonetics ® MCS ® Plus in the total blood volume processed, collection efficiency, procedural time, ACD used, and decrease in donor platelet count during the procedure, while the two machines are comparable in terms of platelet yield, platelet product quality, leukodepletion, and donor safety.…”

Section: Discussionmentioning

confidence: 80%

Comparative assessment of single-donor plateletpheresis by Haemonetics^® MCS^® plus and Trima Accel^®

Baruah

Bajpai

2020

Asian J Transfus Sci

View full text Add to dashboard Cite

BACKGROUND: Single-donor platelets (SDPs) prepared by sophisticated automated equipment offer several advantages over random-donor platelets and are being increasingly used to support thrombocytopenic patients. Different apheresis machines working on the principle of centrifugation are being used worldwide to collect platelets. This retrospective study was done to compare plateletpheresis on two automated cell seperators – Haemonetics ® MCS ® Plus and Trima Accel ® . MATERIALS AND METHODS: Data for 100 single-donor plateletpheresis procedures, fifty on each machine, were retrospectively collected and analyzed. Donor characteristics were analyzed by Student's t -test and no significant difference was found between the two groups. The parameters compared between the two machines were yield, collection efficiency, blood volume processed, procedure time, acid-citrate-dextrose (ACD) used, leukodepletion achieved, quality control of the products, and adverse donor reactions. RESULTS: Platelet yield (3.054 ± 0.14 vs. 3.120 ± 0.25), quality control of the platelets, leukodepletion achieved, and donor safety were comparable in both the machines. The blood volume processed (2230.74 ± 227.01 vs. 2452.90 ± 318.61), ACD used during procedure (265.48 ± 43.21 vs. 298.10 ± 53.32), procedural time (55.92 ± 13.00 vs. 68.86 ± 12.64), and the postprocedural decrease in donor count in Trima Accel ® (183.10 ± 23.99 vs. 161.44 ± 63.47) were significantly less than those in Haemonetics ® MCS ® Plus. The median collection efficiency of Trima Accel ® was found to be greater than Haemonetics ® MCS ® Plus (0.000649 vs. 0.000608, P = 0.020). CONCLUSION: Both Trima Accel ® and Haemonetics ® MCS ® Plus can collect SDPs safely and efficiently. Trima Accel ® has higher collection efficiency and reduced incidence of citrate-related adverse effects. It also has better potential to optimize productivity due to decreased procedural time.

show abstract

“…Moreover, the RBC/WBC removal performance is also compared to commercial plateletpheresis product by comparing the hemoglobin (Hb) level, which serves as an oxygen-transport metalloprotein in red blood cells, before and after platelet separation process. As shown in Table S3 in the Supplementary Information, although the platelet recovery rate is lower than that of our acoustofluidic method, the commercial plateletpheresis has a relatively higher RBCs/WBCs removal rate 58,59 of 93.6% for Amicus, 94.3% for COM.TEC, and 95.5% for Trima, compared to 88.2% achieved at a throughput of 20 mL/min for our acoustofluidic method.…”

Section: Device Performancementioning

confidence: 78%

“…As shown in Fig. 4(f), the platelet collection efficiency of the plastic-based acoustic device was compared to three commercial plateletpheresis systems which were studied by Keklik, M. et al 57 The platelet collection efficiency of our acoustic device can reach a maximum of 92.3%, which is nearly 10% higher than the best performance of commercial plateletpheresis product. Moreover, the RBC/WBC removal performance is also compared to commercial plateletpheresis product by comparing the hemoglobin (Hb) level, which serves as an oxygen-transport metalloprotein in red blood cells, before and after platelet separation process.…”

Section: Device Performancementioning

confidence: 98%

Plastic-based acoustofluidic devices for high-throughput, biocompatible platelet separation

Chen

Wang

et al. 2019

Lab Chip

View full text Add to dashboard Cite

show abstract

Comparison of double dose plateletpheresis on the Fenwal Amicus, Fresenius COM.TEC and Trima Accel cell separators

Cited by 13 publications

References 13 publications

Double Dose Plateletpheresis: A Savior to Shrinking Donor Pool and Platelet Inventory Management

Double Dose Plateletpheresis: A Savior to Shrinking Donor Pool and Platelet Inventory Management

Comparative assessment of single-donor plateletpheresis by Haemonetics^® MCS^® plus and Trima Accel^®

Plastic-based acoustofluidic devices for high-throughput, biocompatible platelet separation

Contact Info

Product

Resources

About

Comparison of double dose plateletpheresis on the Fenwal Amicus, Fresenius COM.TEC and Trima Accel cell separators

Cited by 13 publications

References 13 publications

Double Dose Plateletpheresis: A Savior to Shrinking Donor Pool and Platelet Inventory Management

Double Dose Plateletpheresis: A Savior to Shrinking Donor Pool and Platelet Inventory Management

Comparative assessment of single-donor plateletpheresis by Haemonetics® MCS® plus and Trima Accel®

Plastic-based acoustofluidic devices for high-throughput, biocompatible platelet separation

Contact Info

Product

Resources

About

Comparative assessment of single-donor plateletpheresis by Haemonetics^® MCS^® plus and Trima Accel^®